•  
  •  
  •  
  •  

2025-10-01 22:38:14

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue

Keywords Selected:  ElaraSecuritiesIndia

Research

  • Elara Securities India: FY25 India Union Budget - Bolstering the basics: Fiscal prudence stays
  • Elara Securities India - Diet Report - Ambuja Cements - Cash deployment starts
  • Elara Securities India - Banking & Financials - Retail loans to MFI borrower a risky affair - Sector Update
  • Elara Securities India - Diet Report - Media & Entertainment - Wait turns longer for occupancy revival
  • Elara Securities India - Economics - India: CPI inflation continues to ease
  • Elara Securities India: Automobiles - Tata Motors - Aggressive PV market share target - Company Update - Accumulate - TP: INR 1,100 - Upside: 11%
  • Elara Securities India: Utilities & Renewables - Peak demand ascends to record highs - Monthly Update
  • Elara Securities India - Metals & Mining - Input cost inches up - Monthly Update
  • Elara Securities India-Economics - India: Smooth sailing into H2CY24
  • Elara Securities India - Utilities - PTC India - Trading volumes up by 10% in Q4 - Q4FY24 Update - Reduce - TP INR 207 - Upside: 1%
  • Elara Securities India - Initiating Coverage - Infrastructure - Hindustan Construction - Phoenix Rises - Buy - TP INR 63 - Upside: 65%
  • Elara Securities India - Real Estate - Oberoi Realty - Low-risk compounder - Company Update - Buy - TP: INR 2,350 - Upside: 24%
  • Elara Securities India - Diet Report - Aviation - INDIGO: lagging fleet growth vs rivals
  • Elara Securities India - The IT Inflexion Point - Market Internals with Biju Samuel - Quantitative & Alternate Strategy
  • Elara Securities India - Economics - RBI Policy: Nascent rate cut discussions
  • Elara Securities India-Diet Report - Internet - JioMart to enter qCommerce - execution is key
  • Elara Securities India-India Strategy - Exit Polls: Doubt over long term sustainable rally
  • Elara Securities India-Strategy - Q4FY24 Review - Ending FY24 on good note
  • Elara Securities India-Banking & Financials - Services lifts growth; unsecured growth softens - Sector Update
  • Elara Securities India-Healthcare - Apollo Hospitals Enterprise - New beds impacting margin - Q4FY24 Update/Rating Change - Accumulate - TP INR 6,183 - Upside: 6%
  • Elara Securities India-Economics - India GDP: Upside surprise continues
  • Elara Securities India-Banking & Financials - Rules-based credit model shows vulnerability - Sector Update
  • Elara Securities India - Global Liquidity Tracker: Inflows into India Dedicated Largecap funds continued ahead of Election results. China flows again turn weak
  • Elara Securities India-Banking & Financials - Attention - Still a lot on RBI's radar - Sector Update

Latest Post

  • Hero MotoCorp Ltd dispatches 687,220 units in September 2025
  • Synbiotics Ltd's Amphotericin B Manufacturing Facility receives USFDA approval
  • Veefin has successfully integrated CRIF's Strategy One BRE with our no-code Digital Lending Stack
  • Sentynl Therapeutics updates on its NDA for CUTX-101
  • Unimech Aerospace and Manufacturing Ltd experiences slowdown in revenue


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024